Clonogenic assays on HNSCC cells pre-treated with tocilizumab or SCH772984 demonstrated that both IL-6R and ERK inhibitors act as radiosensitisers for HNSCC cells (Figure 7A,B and Figure S7A). The gene discussed is IL6R; the disease is head and neck squamous cell carcinoma.